| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abc36563c2a61ee841bcf849107b5dfc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfc1d9feba9d94a97ec4cda4aa4cc2e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc58fb40a984948d6d9a9d08cf58bf4e |
| publicationDate |
2010-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2399381-C2 |
| titleOfInvention |
Use of lectins for glycoproteids and antigenic molecules oligomerisation activation |
| abstract |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to biotechnology and concerns the use of lectin or lectin-like molecules for glycoproteids and antigenic molecules oligomerisation activation. Substance of the invention involves a composition presented by one or more noncovalent complexes eliciting an immune response in a patient where each complex contains heat shock protein, antigenic molecule and lectin, and where heat shock protein is glycolised, and where heat shock protein and antigenic molecule are originated from tumour tissue. There also presented methods of manufacturing of such molecular complexes and methods of using the compositions including such molecular complexes for prevention and treatment of cancer and infectious diseases. ^ EFFECT: advantage of the invention consists in increase in activity. ^ 34 cl, 9 ex, 2 tbl, 13 dwg |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11371039-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11248053-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2742606-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2511545-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11597760-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11780912-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11046784-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11359194-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2603467-C2 |
| priorityDate |
2003-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |